Revised SPC: Tysabri (natalizumab) solution for infusion and injection in pre-filled syringe

SPC now notes that thrombocytopenia, including immune thrombocytopenic purpura (ITP), has been reported with use. Patients should any signs of unusual or prolonged bleeding or spontaneous bruising. If thrombocytopenia is identified, discontinuation should be considered.

Source:

electronic Medicines compendium